XSHG
603193
, Last price
Name
Runben Biotechnology Co Ltd
Chart & performance
P/E
—
P/S
—
EPS
0.78
Vol. 1Y
—
Shs. 5Y
5.71%
Rev. 5Y
28.39%
Div Yld LY
—
Div Yld TTM
—
Revenues
1.54b
+17.19%
Net income
315m
+4.78%
CFO
275m
+7.00%
Dividend
Sep 21, 20260.28 /sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Runben Biotechnology Co., Ltd. focuses on the creation, production, and distribution of mosquito repellent solutions, infant care items, and essential oil products. The company primarily sells its offerings through digital sales channels. Established in 2013, Runben Biotechnology is headquartered in Guangzhou, China, and functions as a division of Guangzhou Zhuofan Investment Holding Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||